Biobot Launches COVID-19 Virus Detection via City Wastewater Analysis

Biobot COVID-19 Wastewater Testing, Analysis


Biobot Provides U.S. Cities with Enhanced COVID-19 Mapping via Pro-Bono Wastewater Analysis;
Program is a Collaboration Among Researchers at Biobot, MIT, Harvard, and Brigham and Women’s Hospital


To enhance COVID-19 tracking and trending, Biobot Analytics is applying its technology to analyze biological data from sewers to help identify the spread of SARS-CoV-2, the virus causing COVID-19. Due to limited COVID-19 patient testing, many public health officials do not have the data required to determine the scope of the outbreak, model the pandemic accurately, or respond based on severity.

Biobot’s wastewater analysis can help to increase modeling accuracy without direct interaction with an increasingly strained healthcare system. Biobot analysis provides communities with a dynamic virus map of pandemic changes such as the spread to new areas and a reduction in established hot-spots.

New studies show that SARS-CoV-2 is shed in stool, meaning it’s collecting in sewer systems. “Wastewater epidemiology can help to gauge the level of COVID-19 infection because a broad community or area can be tested rapidly,” said Newsha Ghaeli, Biobot Analytics co-founder and president. “And by identifying SARS-CoV-2 in asymptomatic individuals, Biobot can help public health officials plan more effectively.”

Biobot Supports COVID-19 Epidemiology in Two Ways

1)Biobot is establishing protocols to test sewage for SARS-CoV-2. Biobot, along with researchers at MIT, Harvard, and Brigham and Women’s Hospital, announced a program to map COVID-19 nationally. The researchers are providing the work pro bono; communities only need to cover sample kit and shipping costs ($120 per sample). Communities will collect and ship their samples to Biobot. Learn more about the program at

2)Biobot has boosted its automated sampling to run for seven consecutive days. Expanding sampling from one day to seven, along with additional product ruggedization, builds on an earlier Biobot prototype used during a successful pilot with a North Carolina municipality to improve its understanding of community opioid use. To access product engineering and manufacturing support, Biobot contacted FORGE, a nonprofit organization established by Greentown Labs, the largest cleantech incubator in North America, to support product startups from initial prototyping and design through production.

Through FORGE, Biobot selected Boston Engineering to enhance its product capabilities and design for manufacturability. In 2019, Boston Engineering enhanced Biobot product design and manufactured 12 prototypes. The Biobot product roadmap includes producing advanced prototypes and making additional enhancements for scalable manufacturing. “Working with Boston Engineering, through FORGE’s connection, has been transformative to our work,” said Mariana Matus, CEO and co-founder of Biobot Analytics.

“We are proud to help Biobot scale the availability of its system to provide public health officials with new levels of actionable insight,” said Mark Smithers, chief technology officer for Boston Engineering.

About Biobot Analytics

Inspired by the potential of wastewater epidemiology, Biobot is the first company in the world to commercialize data from sewage. The company’s technology generates public health data that is naturally anonymized yielding unprecedented insight into the health of communities without collecting personal identifiable information. The Biobot technology platform integrates data science, chemistry & biology, and engineering to provide results rapidly and adapt to address emerging public health threats. Biobot is headquartered in the Boston area and is available online at

Medical Device Development

Learn more about our ISO 13485:2016 product development capabilities.

Read More

Biomedical Development

See how we innovate for biotherapeutics and diagnostics companies.

Read More

COVID-19 Response from Medical & Biotech Companies

See how companies are using technology and perseverance to address the pandemic.

Read More